FDG-PET in Predicting Response Rates in Triple-Negative Breast Cancer
the Cancer Therapy Advisor take:
The assessment of metabolic response and epidermal growth factor receptor (EGFR) using fluorodeoxyglucose positron emission tomography (FDG-PET) may assist physicians in predicting the likelihood of achieving pathological complete response (pCR), according to an article published online in the journal Clinical Cancer Research.
The authors of this study aimed to assess the response of metabolic tumors to 18F- FDG-PET compared to using clinicobiological markers to predict pCR to neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC).
Participants included 50 women diagnosed with TNBC and an indication for NAC. Evaluated factors included pre-treatment clinical, biological, and pathological biomarkers (eg, Scarff-Bloom-Richardson [SBR] grade, the Ki-67proliferation index, EGFR).
Furthermore, FDG-PET was used to assess the baseline tumor glucose metabolism and its change after the first cycle of NAC (ΔSUVmax).
Results showed the pCR rate (42%) was associated with a high Ki-67 proliferation index (P=0.016), a negative EGFR result (P=0.042), and a high ΔSUVmax (P=0.002). Negative EGFR status (OR=6.4; P=0.043) and high ΔSUVmax (OR=7.1; P=0.014) were both determined to be independent predictors of pCR.
A combination of a low ΔSUVmax and a positive EGFR status result predicted non-pCR in patients with a 92% accuracy.
Assessment of metabolic response and EGFR using FDG-PET may assist physicians in predicting the likelihood of response.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma